ACKR3 and myeloid sarcoma: However, a prerequisite for such therapies is a sufficient presence of CXCR7 on target cells and as we found that CXCR7 positivity undergoes an overall decrease in MS tissue in comparison to controls this is a critical aspect with potential therapeutic implications.